MAGNETISMM-32
Research type
Research Study
Full title
A PHASE 3, OPEN-LABEL STUDY OF ELRANATAMAB MONOTHERAPY VERSUS ELOTUZUMAB, POMALIDOMIDE, DEXAMETHASONE (EPd) OR POMALIDOMIDE, BORTEZOMIB, DEXAMETHASONE (PVd) OR CARFILZOMIB, DEXAMETHASONE (Kd) IN PARTICIPANTS WITH RELAPSED/ REFRACTORY MULTIPLE MYELOMA WHO RECEIVED PRIOR ANTI-CD38 DIRECTED THERAPY
IRAS ID
1008900
Contact name
Nathalie Bouxin
Contact email
Sponsor organisation
Pfizer Inc.
Clinicaltrials.gov Identifier
Research summary
The purpose of this study is to compare elranatamab to other commonly used medicines for the treatment of multiple myeloma (MM) in participants who have previously received treatment with an anti-CD38 antibody. There is currently no standard of care available for this patient population.
This study is seeking participants with MM who:
• Are 18 years of age or older.
• Have received 1 to 4 treatments before for MM, including an anti-CD38 antibody
• Have MM that has returned or not responded to their most recent treatment.Half of the participants will receive elranatamab. The other half will receive a combination therapy selected by the study doctor, either Elotuzumab, Pomalidomide, Dexamethasone or Pomalidomide, Bortezomib, Dexamethasone or Carfilzomib, Dexamethasone.
Elranatamab will be given subcutaneously (as a shot under the skin) at the study clinic about once a week. The frequency may be reduced later in the study.
The medicines in the combination therapy will be taken by mouth (at home or at the study clinic) AND either as:
• a subcutaneous shot at the study clinic
• through a needle in the vein at the study clinic. The frequency will depend on what combination the study doctor selects.
Participants may continue to receive elranatamab or combination therapy until their MM is no longer responding. The study team will see how each participant is doing during regular visits at the study clinic. The study team will continue to follow-up with participants after study treatment with telephone contacts (or visits). Participants are asked to take part in the study for about 5 years.
The study will compare the experiences of people receiving elranatamab to those people receiving a combination therapy. This will help learn how safe and effective elranatamab is.
The Sponsor (Pfizer) is providing funding to conduct this study.REC name
Wales REC 2
REC reference
24/WA/0001
Date of REC Opinion
5 Mar 2024
REC opinion
Further Information Favourable Opinion